Drug Profile

CTX 8573

Alternative Names: CTX-8573

Latest Information Update: 09 Mar 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Compass Therapeutics
Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Autoimmune disorders; Haematological malignancies

Most Recent Events

01 Jan 2021 Discontinued - Preclinical for Autoimmune disorders in USA (Parenteral)
01 Jan 2021 Discontinued - Preclinical for Haematological malignancies in USA (Parenteral)
16 Dec 2019 Compass Therapeutics plans to file an IND for Multiple myeloma or Autoimmune disorders in the first half of 2020

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com